SEC Form 4 · accession 0001209191-16-112619
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Edgar Engleman
Director · 10% Owner
Period of report
Mar 28, 2016
Accepted (ET)
Apr 4, 2016 · 7:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $15.75 | Mar 28, 2016 | A | 25,000 | A | — | Mar 28, 2026 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option vests in equal monthly installments over 12 months measured from March 28, 2016 subject to Reporting Person's continuous service status as of each such date.
- F2The option is subject to shareholder approval of an amendment to the Celladon Corporation 2013 Equity Incentive Plan. This is a voluntary early filing.